Otulfi® (ustekinumab-aauz), a biosimilar to Stelara®, now available in a 45 mg/0.5 mL single dose vial from Fresenius Kabi. Otulfi ® is a prescription medicine and the brand name for Fresenius Kabi’s ...
Fresenius Kabi, an Operating Company of Fresenius, and a leading provider of essential medicines and medical technologies, announced today it has introduced a new presentation of Otulfi ® (ustekinumab ...
Ladies and gentlemen, the program is about to begin. At this time, it is my pleasure to turn the program over to your host, Joanna Gajuk. Thank you. Thank you. Thanks, everyone, for joining us. Again, ...
Steqeyma, Celltrion’s Stelara (ustekinumab) biosimilar, won Medsafe approval in New Zealand with all originator uses, marking the country’s first Stelara copycat. (Courtesy of Celltrion) Celltrion ...
A new biosimilar, SYSA1902, shows comparable efficacy and safety to ustekinumab for treating moderate-to-severe plaque psoriasis, expanding patient options. A new biosimilar may offer a treatment ...
RALEIGH, N.C., Aug. 18, 2025 /PRNewswire/ -- Accord BioPharma, Inc., the specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology ...
Prefilled syringes of Imuldosa now have the lowest wholesaler acquisition cost among all branded ustekinumab biosimilars, according to a news release. Accord BioPharma announced today the commercial ...
Celltrion's FDA approval of Steqeyma enhances pediatric psoriasis treatment, offering flexible dosing options for children with chronic inflammatory conditions. Celltrion announced the FDA had ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results